| Johnson & Johnson (JNJ) | $94.19B | 28.5% | 38.8× | $615.87B |
| Eli Lilly & Co. (LLY) | $65.18B | 31.7% | 42.2× | $1.12T |
| Merck & Co., Inc. (MRK) | $65.01B | 28.1% | 115.8× | $360.08B |
| Pfizer Inc. (PFE) | $62.58B | 12.4% | 38.9× | $168.60B |
| AbbVie Inc. (ABBV) | $61.16B | 6.9% | 80.6× | $504.37B |
| Bristol Myers Squibb Co. (BMY) | $48.19B | 14.6% | 13.2× | $122.05B |
| Abbott Laboratories (ABT) | $44.33B | 14.7% | 33.8× | $181.50B |
| Teva Pharmaceutical Industries Ltd. (TEVA) | $17.26B | 8.2% | 70.3× | $48.40B |
| Regeneron Pharmaceuticals, Inc. (REGN) | $14.34B | 31.4% | 19.6× | $81.41B |
| Viatris Inc (VTRS) | $14.25B | -24.7% | — | $20.93B |
| Vertex Pharmaceuticals Inc. (VRTX) | $12.00B | 32.9% | 28.9× | $126.66B |
| Bausch Health Companies Inc. (BHC) | $10.27B | 1.5% | — | $2.22B |
| Zoetis Inc. (ZTS) | $9.47B | 28.2% | 13.1× | $32.80B |
| Organon & Co. (OGN) | $6.22B | 3.0% | 17.6× | $3.61B |
| BeOne Medicines Ltd. (ONC) | $5.34B | 5.4% | 66.0× | $41.99B |
| Elanco Animal Health Inc (ELAN) | $4.71B | -4.9% | — | $11.26B |
| Jazz Pharmaceuticals plc (JAZZ) | $4.27B | -8.3% | — | $13.61B |
| PERRIGO Co plc (PRGO) | $4.25B | -33.5% | — | $2.28B |
| Alnylam Pharmaceuticals, Inc. (ALNY) | $3.71B | 8.4% | 39.1× | $31.02B |
| Biomarin Pharmaceutical Inc. (BMRN) | $3.22B | 10.8% | 149.0× | $10.67B |
| UNITED THERAPEUTICS Corp (UTHR) | $3.18B | 41.9% | 19.1× | $22.87B |
| Amneal Pharmaceuticals, Inc. (AMRX) | $3.02B | 2.4% | 38.6× | $6.58B |
| Royalty Pharma plc (RPRX) | $2.38B | 32.4% | 32.4× | $35.22B |
| Sarepta Therapeutics, Inc. (SRPT) | $2.20B | -32.5% | — | $1.89B |
| Ptc Therapeutics, Inc. (PTCT) | $1.73B | 39.4% | — | $5.40B |
| Phibro Animal Health Corp. (PAHC) | $1.52B | 6.6% | 15.4× | $1.49B |
| Alkermes plc. (ALKS) | $1.48B | 16.4% | 105.6× | $6.56B |
| Indivior Pharmaceuticals, Inc. (INDV) | $1.24B | 16.9% | 11.6× | $3.83B |
| Nasus Pharma Ltd (NSRX) | $1.24B | -0.5% | — | $37.2M |
| Prestige Consumer Healthcare Inc. (PBH) | $1.09B | 17.5% | 14.0× | $2.36B |
| Acadia Pharmaceuticals Inc. (ACAD) | $1.07B | 36.5% | 8.4× | $3.40B |
| Madrigal Pharmaceuticals, Inc. (MDGL) | $958.4M | -30.1% | — | $10.90B |
| Ionis Pharmaceuticals Inc. (IONS) | $943.7M | -40.4% | — | $7.52B |
| Ani Pharmaceuticals Inc. (ANIP) | $883.4M | 8.9% | 15.3× | $1.63B |
| Harmony Biosciences Holdings, Inc. (HRMY) | $868.5M | 18.3% | 13.0× | $2.35B |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | $829.4M | -0.2% | — | $8.58B |
| Collegium Pharmaceutical, Inc. (COLL) | $780.6M | 8.1% | 18.3× | $755.0M |
| Corcept Therapeutics Inc. (CORT) | $761.4M | 13.1% | 244.8× | $11.91B |
| Emergent BioSolutions Inc. (EBS) | $742.9M | 7.1% | — | $362.0M |
| Pacira BioSciences, Inc. (PCRX) | $726.4M | 1.0% | 103.7× | $1.45B |
| Amphastar Pharmaceuticals, Inc. (AMPH) | $719.9M | 13.6% | 15.4× | $1.11B |
| Supernus Pharmaceuticals, Inc. (SUPN) | $719.0M | -5.4% | — | $2.48B |
| Kiniksa Pharmaceuticals International, plc (KNSA) | $677.6M | 8.7% | 79.3× | $6.13B |
| Ultragenyx Pharmaceutical Inc. (RARE) | $673.0M | -85.4% | — | $1.53B |
| Axsome Therapeutics, Inc. (AXSM) | $638.5M | -28.7% | — | $8.47B |
| Tg Therapeutics, Inc. (TGTX) | $616.3M | 72.6% | 20.1× | $8.48B |
| Opko Health, Inc. (OPK) | $606.9M | -37.2% | — | $1.03B |
| INSMED Inc (INSM) | $606.4M | — | — | $21.02B |
| Catalyst Pharmaceuticals, Inc. (CPRX) | $589.0M | 36.4% | 18.2× | $3.85B |
| Organogenesis Holdings Inc. (ORGO) | $564.2M | 6.6% | — | $158.3M |
| HUTCHMED (China) Ltd (HCM) | $548.5M | 83.3% | 141.0× | $2.45B |
| Mirum Pharmaceuticals, Inc. (MIRM) | $521.3M | -4.5% | — | $5.59B |
| BridgeBio Pharma, Inc. (BBIO) | $502.1M | — | — | $12.98B |
| Travere Therapeutics, Inc. (TVTX) | $490.7M | -5.2% | — | $4.90B |
| Natures Sunshine Products Inc. (NATR) | $480.1M | 4.1% | 12.6× | $223.6M |
| Zai Lab Ltd (ZLAB) | $457.2M | -38.4% | — | $2.59B |
| Innoviva, Inc. (INVA) | $411.3M | 65.9% | 5.0× | $1.55B |
| Ardelyx, Inc. (ARDX) | $407.3M | -15.1% | — | $833.9M |
| Esperion Therapeutics, Inc. (ESPR) | $403.1M | -5.6% | — | $819.5M |
| Sinovac Biotech Ltd. (SVA) | $386.0M | -51.5% | — | — |
| Arcutis Biotherapeutics, Inc. (ARQT) | $372.1M | -4.3% | — | $3.30B |
| Mannkind Corp. (MNKD) | $349.0M | 1.7% | — | $1.01B |
| CorMedix Inc. (CRMD) | $311.7M | 52.3% | 3.6× | $581.5M |
| Evolus, Inc. (EOLS) | $297.2M | -17.4% | — | $511.9M |
| Ironwood Pharmaceuticals Inc. (IRWD) | $296.2M | 8.1% | 4.9× | $621.3M |
| Rigel Pharmaceuticals Inc. (RIGL) | $294.3M | — | 2.9× | $911.8M |
| Xeris Biopharma Holdings, Inc. (XERS) | $291.8M | 0.2% | — | $1.91B |
| Aurinia Pharmaceuticals Inc. (AUPH) | $283.1M | — | 7.2× | $2.20B |
| Harrow, Inc. (HROW) | $272.3M | -1.9% | — | $1.09B |
| Vireo Growth Inc. (VREOF) | $268.8M | -25.3% | — | $466.7M |
| Ligand Pharmaceuticals Inc. (LGND) | $268.1M | 46.4% | 31.1× | $5.88B |
| Arvinas, Inc. (ARVN) | $262.6M | -30.8% | — | $449.7M |
| Schrodinger, Inc. (SDGR) | $255.9M | -40.4% | — | $1.94B |
| Arcus Biosciences, Inc. (RCUS) | $247.0M | — | — | $2.83B |
| Keros Therapeutics, Inc. (KROS) | $243.9M | 35.7% | — | $219.1M |
| Akebia Therapeutics, Inc. (AKBA) | $236.2M | -2.3% | — | $185.7M |
| Anaptysbio, Inc. (ANAB) | $234.6M | -5.6% | — | $1.39B |
| Puma Biotechnology, Inc. (PBYI) | $228.4M | 13.6% | 20.0× | $526.5M |
| IDEAYA Biosciences, Inc. (IDYA) | $218.7M | -52.0% | — | $3.27B |
| Vanda Pharmaceuticals Inc. (VNDA) | $216.1M | — | — | $243.7M |
| Amarin Corp. Plc\uk (AMRN) | $213.6M | -18.2% | — | $244.4M |
| Rhythm Pharmaceuticals, Inc. (RYTM) | $189.8M | — | — | $5.93B |
| Maravai Lifesciences Holdings, Inc. (MRVI) | $185.7M | -70.4% | — | $2.42B |
| Stoke Therapeutics, Inc. (STOK) | $184.4M | -3.7% | — | $1.56B |
| Lifevantage Corp (LFVN) | $182.6M | 2.8% | 15.0× | $75.5M |
| Cryoport, Inc. (CYRX) | $176.2M | 44.4% | — | $842.8M |
| Phathom Pharmaceuticals, Inc. (PHAT) | $175.1M | — | — | $606.8M |
| Syndax Pharmaceuticals Inc (SNDX) | $172.4M | — | — | $1.15B |
| Liquidia Corp (LQDA) | $158.3M | -43.5% | — | $3.11B |
| Heron Therapeutics, Inc. (HRTX) | $154.9M | -13.0% | — | $71.5M |
| Macrogenics Inc. (MGNX) | $149.5M | -49.9% | — | $214.7M |
| Elite Pharmaceuticals Inc. (ELTP) | $148.9M | 30.1% | 6.3× | $269.3M |
| Karyopharm Therapeutics Inc. (KPTI) | $146.1M | — | — | $8.0M |
| Lifecore Biomedical, Inc. \de\ (LFCR) | $128.9M | -30.0% | — | $244.1M |
| Xencor Inc (XNCR) | $125.6M | -73.2% | — | $1.70B |
| Gyre Therapeutics, Inc. (GYRE) | $116.6M | 8.5% | — | $678.6M |
| UroGen Pharma Ltd. (URGN) | $109.8M | — | — | $1.69B |
| Theravance Biopharma, Inc. (TBPH) | $107.5M | 98.5% | 16.4× | $884.2M |
| Zevra Therapeutics, Inc. (ZVRA) | $106.5M | 78.2% | 10.8× | $590.3M |
| Zymeworks Inc. (ZYME) | $106.0M | -76.6% | — | $1.80B |
| Siga Technologies Inc. (SIGA) | $94.6M | 24.6% | — | $227.8M |
| Cytokinetics Inc. (CYTK) | $88.0M | — | — | $8.82B |
| LakeShore Biopharma Co., Ltd. (LSBCF) | $85.7M | -16.3% | — | — |
| Standard Biotools Inc. (LAB) | $85.3M | -87.8% | — | $258.5M |
| ARS Pharmaceuticals, Inc. (SPRY) | $84.3M | — | — | $399.8M |
| Nurix Therapeutics, Inc. (NRIX) | $84.0M | — | — | $2.73B |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $82.0M | -80.2% | — | $358.4M |
| ADC Therapeutics SA (ADCT) | $81.4M | — | — | $217.0M |
| Eton Pharmaceuticals, Inc. (ETON) | $80.0M | -5.8% | — | $1.47B |
| CytomX Therapeutics, Inc. (CTMX) | $76.2M | -22.8% | — | $485.9M |
| AbCellera Biologics Inc. (ABCL) | $75.1M | — | — | $4.09B |
| Bicycle Therapeutics PLC (BCYC) | $72.6M | — | — | $245.7M |
| Assembly Biosciences, Inc. (ASMB) | $72.3M | -8.5% | — | $414.1M |
| Viridian Therapeutics, Inc.\DE (VRDN) | $70.8M | — | — | $2.16B |
| Rockwell Medical, Inc. (RMTI) | $69.3M | -7.7% | — | $29.9M |
| Kura Oncology, Inc. (KURA) | $67.5M | — | — | $862.9M |
| Spero Therapeutics, Inc. (SPRO) | $66.8M | 12.8% | 7.9× | $64.1M |
| Enanta Pharmaceuticals Inc. (ENTA) | $65.3M | — | — | $334.1M |
| Nuvation Bio Inc. (NUVB) | $62.9M | — | — | $1.56B |
| Tango Therapeutics, Inc. (TNGX) | $62.4M | — | — | $4.01B |
| Journey Medical Corp (DERM) | $61.2M | -18.7% | — | $160.3M |
| Fortress Biotech, Inc. (FBIO) | $61.2M | 11.1% | 0.7× | $65.0M |
| Aytu Biopharma, Inc. (AYTU) | $57.6M | -24.8% | — | $21.2M |
| Nektar Therapeutics (NKTR) | $55.2M | — | — | $1.29B |
| Agios Pharmaceuticals, Inc. (AGIO) | $54.0M | — | — | $1.93B |
| Q32 Bio Inc. (QTTB) | $53.7M | 55.5% | 2.4× | $223.9M |
| XOMA Royalty Corp (XOMA) | $52.1M | 60.8% | 25.6× | $710.2M |
| Ocular Therapeutix, Inc. (OCUL) | $52.0M | — | — | $1.62B |
| Lexicon Pharmaceuticals, Inc. (LXRX) | $49.8M | — | — | $676.3M |
| Gossamer Bio, Inc. (GOSS) | $48.5M | — | — | $54.4M |
| Protagonist Therapeutics, Inc (PTGX) | $46.0M | — | — | $9.37B |
| Septerna, Inc. (SEPN) | $46.0M | — | — | $1.79B |
| Aquestive Therapeutics, Inc. (AQST) | $44.5M | — | — | $603.7M |
| Cumberland Pharmaceuticals Inc. (CPIX) | $44.5M | -6.4% | — | $112.2M |
| Integrated Biopharma Inc. (INBP) | $43.9M | -6.5% | — | $5.6M |
| Xilio Therapeutics, Inc. (XLO) | $43.8M | -80.1% | — | $59.6M |
| Wave Life Sciences, Inc. (WVE) | $42.7M | — | — | $616.8M |
| Biofrontera Inc. (BFRI) | $41.7M | -25.3% | — | $12.3M |
| BGM Group Ltd. (BGM) | $37.9M | -52.6% | — | $140.0M |
| Lftd Partners Inc. (LIFD) | $36.9M | -67.3% | — | $1.5M |
| Sunshine Biopharma Inc. (SBFM) | $36.3M | -16.5% | — | $1.5M |
| Earth Science Tech, Inc. (ETST) | $35.7M | 10.2% | 9.0× | $25.9M |
| Verrica Pharmaceuticals Inc. (VRCA) | $35.6M | -50.3% | — | $70.6M |
| Bioharvest Sciences Inc. (BHST) | $34.5M | -32.3% | — | $39.6M |
| Zomedica Corp. (ZOMDF) | $32.0M | — | — | $81.3M |
| Verastem, Inc. (VSTM) | $30.9M | — | — | $758.9M |
| Foghorn Therapeutics Inc. (FHTX) | $30.9M | — | — | $112.2M |
| Cue Biopharma, Inc. (CUE) | $27.5M | -96.9% | — | $135.1M |
| Celularity Inc (CELU) | $26.6M | — | — | $42.5M |
| Entrada Therapeutics, Inc. (TRDA) | $25.4M | — | — | $170.2M |
| Alumis Inc. (ALMS) | $24.1M | — | — | $913.8M |
| NewAmsterdam Pharma Co N.V. (NAMS) | $22.5M | — | — | $2.32B |
| CASI Pharmaceuticals, Inc. (CASIF) | $20.7M | — | — | $2.1M |
| Scynexis Inc. (SCYX) | $20.6M | -41.8% | — | $36.5M |
| Evofem Biosciences, Inc. (EVFM) | $20.2M | 1.9% | — | $927,710 |
| Sol-Gel Technologies Ltd. (SLGL) | $19.4M | -31.6% | — | $235.0M |
| Universe Pharmaceuticals INC (UPC) | $17.9M | -20.6% | — | $20.9M |
| Zhengye Biotechnology Holding Ltd (ZYBT) | $16.6M | -60.0% | — | $82.0M |
| uniQure N.V. (QURE) | $16.1M | — | — | $1.51B |
| Opus Genetics, Inc. (IRD) | $14.2M | — | — | $336.9M |
| Arbutus Biopharma Corp (ABUS) | $14.1M | — | — | $646.8M |
| Pyxis Oncology, Inc. (PYXS) | $13.9M | — | — | $200.7M |
| CV Sciences, Inc. (CVSI) | $13.8M | -6.9% | — | $2.3M |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | $13.1M | — | — | $125.2M |
| Evommune, Inc. (EVMN) | $13.0M | — | — | $187.6M |
| Emmaus Life Sciences, Inc. (EMMA) | $12.5M | -60.2% | — | $4.1M |
| Prelude Therapeutics Inc (PRLD) | $12.1M | — | — | $310.4M |
| Jaguar Health, Inc. (JAGX) | $11.5M | — | — | $6.9M |
| Crescent Biopharma, Inc. (CBIO) | $10.8M | — | — | $463.6M |
| Janux Therapeutics, Inc. (JANX) | $10.0M | — | — | $1.01B |
| Zenas BioPharma, Inc. (ZBIO) | $10.0M | — | — | $1.78B |
| Prothena Corp. Public Ltd. Co. (PRTA) | $9.7M | — | — | $428.7M |
| Roivant Sciences Ltd. (ROIV) | $8.3M | — | — | $24.22B |
| Aclaris Therapeutics, Inc. (ACRS) | $7.8M | — | — | $482.8M |
| Adagene Inc. (ADAG) | $7.7M | — | — | $138.3M |
| Whitehawk Therapeutics, Inc. (WHWK) | $7.1M | — | — | $200.7M |
| Immunome Inc. (IMNM) | $6.9M | — | — | $1.94B |
| Kyntra Bio, Inc. (KYNB) | $6.4M | — | — | $19.6M |
| ProPhase Labs, Inc. (PRPH) | $4.3M | — | — | $155,925 |
| Cartesian Therapeutics, Inc. (RNAC) | $2.8M | — | — | $213.5M |
| Lipocine Inc. (LPCN) | $2.0M | — | — | $12.9M |
| Neuphoria Therapeutics Inc. (NEUP) | $1.2M | — | — | $17.9M |
| Silence Therapeutics plc (SLN) | $559,000 | — | — | $612.8M |
| Mereo BioPharma Group plc (MREO) | $500,000 | — | — | $48.4M |
| Lite Strategy, Inc. (LITS) | $267,000 | — | — | $36.3M |
| Connect Biopharma Holdings Ltd (CNTB) | $64,000 | — | — | $57.2M |
| Amylyx Pharmaceuticals, Inc. (AMLX) | $0 | — | — | $3.47B |
| Barinthus Biotherapeutics plc. (BRNS) | $0 | — | — | $30.2M |
| Capricor Therapeutics, Inc. (CAPR) | $0 | — | — | $383.1M |
| Fulcrum Therapeutics, Inc. (FULC) | $0 | — | — | $280.3M |
| Kiora Pharmaceuticals Inc. (KPRX) | $0 | — | — | $10.6M |
| Spruce Biosciences, Inc. (SPRB) | $0 | — | — | $126.6M |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | $0 | — | — | $209.0M |
| Contineum Therapeutics, Inc. (CTNM) | — | — | — | $316.8M |
| Equillium, Inc. (EQ) | — | — | — | $83.7M |
| Palvella Therapeutics, Inc. (PVLA) | — | — | — | $1.73B |
| Tvardi Therapeutics, Inc. (TVRD) | — | — | — | $13.7M |
| Veru Inc. (VERU) | — | — | — | $41.9M |
